EU Finds No Increase In Cancer Risk From Diabetes Drugs

Law360, New York (July 26, 2013, 3:26 PM EDT) -- The European Medicines Agency said Friday that its research into diabetes drugs made by Merck & Co. Inc., AstraZeneca PLC and others does not show an increased risk of precancerous changes in the pancreas.

The EMA and the U.S. Food and Drug Administration launched investigations into the drugs in March based on an article published in the medical journal Diabetes that suggested a class of Type 2 diabetes drug called incretin mimetics may lead to an increased risk of pancreatitis and precancerous cellular changes known as...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.